11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial

BACKGROUND: Clinical trials have shown that trastuzumab, a recombinant monoclonal antibody against HER2 receptor, significantly improves overall survival and disease-free survival in women with HER2-positive early breast cancer, but long-term follow-up data are needed. We report the results of compa...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Lancet
Asıl Yazarlar: Cameron, David, Piccart-Gebhart, Martine J, Gelber, Richard D, Procter, Marion, Goldhirsch, Aron, de Azambuja, Evandro, Castro, Gilberto, Untch, Michael, Smith, Ian, Gianni, Luca, Baselga, Jose, Al-Sakaff, Nedal, Lauer, Sabine, McFadden, Eleanor, Leyland-Jones, Brian, Bell, Richard, Dowsett, Mitch, Jackisch, Christian
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2017
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5465633/
https://ncbi.nlm.nih.gov/pubmed/28215665
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S0140-6736(16)32616-2
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller